ERCC2 and nasopharyngeal carcinoma: Hence, if hOGG1 Ser326Cys, ITGA2 C807T and XPD Lys751Gln polymorphisms from the current study are verified to be valid diagnostic markers for NPC patients, the possibility exists for customizing screening modalities for high risk individuals, such as those with a family history of NPC.